Daan Gene Co., Ltd. (DAAN GENE CO LTD) aksje

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, public health, tumor maker, and nucleic acid extraction, as well as polymerase chain reaction, sample preparation, and nucleic extraction systems for molecular diagnosis; COVID-19 rapid test kit and chemiluminescence immunoassay analyzers for immunoassay; liquid based cytology production and automatic sample transfer machines for pathology tests; and auto biochemistry analyzers and chemistry reagents for clinical chemistry. It also provides medical laboratory and health consultation services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services. The company sells its products under the Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech brands. In addition, it is involved in biological technology, biomedicine and biopharmaceutical, clinical test, business, software development, trading, hospital investment management, capital market, insurance agent, management, finance lease, microfinance, commercial factoring, loan, consulting, and technology promotion and application service industry services. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. Daan Gene Co., Ltd. was founded in 1988 and is headquartered in Guangzhou, China.